V132 vaccine safety in healthy older adults
Official title: A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants
Run by Merck Sharp & Dohme LLC · NCT07712575 · Data updated 2026-11-12
This study tests the safety and immune response of V132 formulations in healthy older adults to see if the vaccine is safe and prompts an immune reaction.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 75 Years |
| Sex | All |
| Enrollment | 280 (estimated) |
| Sponsor | Merck Sharp & Dohme LLC Industry-sponsored |
| Locations | 10 sites (Anaheim, California and 9 other locations) |
| Status | Recruiting |
| Started | August 12, 2026 |
| Main results expected | May 5, 2028 |
| Study ends | May 5, 2028 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07712575 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged older than 60 with BMI between 18.0 and 35.0 kg/m^2 who have no recent history of invasive or culture-positive pneumococcal disease and no prior pneumococcal vaccines within specified windows.
✕Probably not a fit
Individuals with recent pneumococcal disease, recent or any prior pneumococcal conjugate vaccination, or other significant health issues may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1 trial evaluates multiple formulations of the V132 vaccine in healthy adults aged older than 60. Participants receive one of several V132 formulations or comparator vaccines to monitor safety and immune responses. The study excludes individuals with recent pneumococcal disease or prior pneumococcal vaccines within specified timeframes. Sites are located in California and Florida, enrolling participants in a controlled clinical setting with routine follow-up visits. Data will inform whether V132 can safely provoke an immune response in this population.
Why it matters
Potential benefit: If successful, participants may gain information about the vaccine's safety and potential immune benefits for older adults.
How similar studies have gone: Past pneumococcal vaccine studies have shown acceptable safety and immunogenicity in similar populations, though this specific V132 formulation set is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive) Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination * Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
Where it's running
-
Anaheim Clinical Trials ( Site 0006)
Anaheim, California, United States Recruiting -
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida, United States Recruiting -
Research Centers of America ( Hollywood ) ( Site 0009)
Hollywood, Florida, United States Recruiting -
QPS-MRA, LLC-Early Phase ( Site 0001)
South Miami, Florida, United States Recruiting -
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
Springfield, Missouri, United States Recruiting -
Velocity Clinical Research Lincoln ( Site 0007)
Lincoln, Nebraska, United States Recruiting
Show 4 more locations
-
Velocity Clinical Research, Omaha ( Site 0008)
Omaha, Nebraska, United States Recruiting -
Remington-Davis, Inc. ( Site 0005)
Columbus, Ohio, United States Recruiting -
Velocity Clinical Research, Providence ( Site 0010)
East Greenwich, Rhode Island, United States Recruiting -
University of Texas Medical Branch ( Site 0004)
League City, Texas, United States Recruiting
Study contacts
- Study coordinator: Toll Free Number
- Email: Trialsites@msd.com
- Phone: 1-888-577-8839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.